XML 13 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenues:        
Revenue under collaborative research and development arrangements $ 351,272 $ 2,327,316 $ 20,998,174 $ 6,014,161
Revenue under collaborative research and development arrangements with affiliated entities 129,133 574,596 539,342 1,211,316
Grants and miscellaneous revenue 1,456,216 9,410,648 9,494,096 19,401,029
Grants and miscellaneous revenue from affiliated entity 707,922 227,903 2,401,240 227,903
Total revenues 2,644,543 12,540,463 33,432,852 26,854,409
Operating expenses:        
Research and development 25,510,239 26,980,343 73,931,494 64,800,304
General and administrative 6,319,775 5,755,603 20,256,470 16,926,746
Gain on sale of assets 0 0 0 (1,000,000)
Total operating expenses 31,830,014 32,735,946 94,187,964 80,727,050
Loss from operations (29,185,471) (20,195,483) (60,755,112) (53,872,641)
Other income (expense):        
Interest and other income, net 463,346 391,596 1,103,708 1,065,797
Change in fair value of common stock warrants, net 423,296 2,690 227,273 (517,334)
Gain (loss) on investment in affiliated entity (5,835,741) (958,141) (7,275,462) 5,817,309
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (34,134,570) $ (20,759,338) $ (66,699,593) $ (47,506,869)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders        
Basic (in dollars per share) $ (0.39) $ (0.28) $ (0.85) $ (0.65)
Diluted (in dollars per share) $ (0.40) $ (0.28) $ (0.85) $ (0.65)
Weighted average number of common shares outstanding        
Basic (in shares) 86,952,024 73,602,834 78,894,881 72,932,199
Diluted (in shares) 87,090,683 73,789,008 79,043,480 72,932,199